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Abstract. 
 
Constitutively activated Ras proteins are
associated with a large number of human cancers, in-
cluding those originating from skeletal muscle tissue. In
this study, we show that ectopic expression of oncogenic
Ras stimulates proliferation of the MM14 skeletal mus-
cle satellite cell line in the absence of exogenously
added ﬁbroblast growth factors (FGFs). MM14 cells ex-
press FGF-1, -2, -6, and -7 and produce FGF protein,
yet they are dependent on exogenously supplied FGFs
to both maintain proliferation and repress terminal dif-
ferentiation. Thus, the FGFs produced by these cells are
either inaccessible or inactive, since the endogenous
FGFs elicit no detectable biological response. Onco-
genic Ras-induced proliferation is abolished by addition
 
of an anti–FGF-2 blocking antibody, suramin, or treat-
ment with either sodium chlorate or heparitinase, demon-
strating an autocrine requirement for FGF-2. Oncogenic
 
Ras does not appear to alter cellular export rates of
 
FGF-2, which does not possess an NH
 
2
 
-terminal or in-
ternal signal peptide. However, oncogenic Ras does
appear to be involved in releasing or activating inactive,
extracellularly sequestered FGF-2. Surprisingly, inhibit-
ing the autocrine FGF-2 required for proliferation has
no effect on oncogenic Ras-mediated repression of
muscle-speciﬁc gene expression. We conclude that on-
cogenic Ras-induced proliferation of skeletal muscle
cells is mediated via a unique and novel mechanism
that is distinct from Ras-induced repression of terminal
differentiation and involves activation of extracellu-
larly localized, inactive FGF-2.
Key words: mutant • Ras • myoblasts • FGF-2 •
proliferation
 
Introduction
 
Ras is a multifunctional signaling molecule acting as an es-
sential component of signal transduction pathways that
regulate cellular physiology (Campbell et al., 1998). Mem-
bers of the Ras family of proteins that are constitutively ac-
tivated by point mutations play a major role in the onset of
a large number of human cancers, including those originat-
ing from skeletal muscle tissue (Yoo et al., 1999). Rhab-
domyosarcomas are the most common soft tissue sarcomas
in children and adolescents. These skeletal muscle tumors
are incapable of differentiation and thus do not withdraw
from the cell cycle. Up to 35% of these tumors contain ac-
tivating Ras point mutations, suggesting a major involve-
ment of Ras in rhabdomyosarcomas (Stratton et al., 1989).
 
Constitutively active Ras mutants stimulate secretion of
growth and angiogenic factors (Rak et al., 1995), poten-
tially allowing neoplastic cells to overcome growth restric-
tions in their normal tissue environment. In skeletal mus-
cle cells, activated Ras mutants have been shown to
promote secretion of an unidentified factor that can re-
press myogenic differentiation and may participate in the
development of rhabdomyosarcomas (Weyman and Wolf-
man, 1997). Of particular interest is the observation that
cultured human embryonal rhabdomyosarcoma cells ex-
 
press the 
 
fgf-2
 
 gene and produce biologically active FGF-2
(Schweigerer et al., 1987). Release of FGF-2 may stimulate
the growth and neovascularization of human rhabdomyo-
sarcomas and contribute to tumor development. Although
ectopic expression of oncogenic Ha-Ras in myogenic cell
lines represses terminal differentiation, it is not reported
to elicit a proliferative response (Olson et al., 1987; Ko-
nieczny et al., 1989; Weyman and Wolfman, 1997). From
these studies, it has been concluded that Ras inhibits mus-
cle differentiation without affecting proliferative response
pathways. FGFs are likely candidates for such factors since
they play critical roles in regulation of skeletal muscle dif-
ferentiation in cultured cells (Linkhart et al., 1981; Allen et
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al., 1985; Kardami et al., 1985; Seed and Hauschka, 1988;
Rando and Blau, 1994; Flanagan-Steet et al., 2000), in skel-
etal muscle development in vivo (Flanagan-Steet et al.,
2000), and in skeletal muscle regeneration (Anderson et
al., 1995; Floss et al., 1997).
MM14 myoblasts express FGF-1, -2, -6, and -7 but are
absolutely dependent on exogenously supplied FGFs to
repress myogenesis and promote cell proliferation (Clegg
et al., 1987; Hannon et al., 1996; Fedorov et al., 1998;
Kudla et al., 1998). FGF-2 is one of four FGFs that do not
possess signal peptides and do not use the classical ER/
Golgi-dependent secretory pathways for export from the
cell (Florkiewicz et al., 1995). Since ectopically expressed
Ha-Ras can repress differentiation of MM14 cells (Fed-
orov et al., 1998), we asked if Ha-Ras was capable of stim-
ulating proliferation in MM14 cells. Here we report that
constitutively active Ras stimulates MM14 myoblast pro-
liferation via a novel mechanism that is dependent on ex-
port of endogenously produced FGF-2 and subsequent re-
lease or activation of the exported FGF-2. Moreover, we
also found that the signaling pathways used by oncogenic
Ras to stimulate proliferation and repress differentiation
in myogenic cells are distinct and mediated independently.
 
Materials and Methods
 
Cell Culture
 
Mouse MM14 cells (Lim and Hauschka, 1984) were cultured as described
previously (Kudla et al., 1995). BaF3/FR1 cells, a BaF3 cell clone stably
expressing FGF receptor (FGFR)
 
1
 
-1, was cultured as described by Ornitz
et al. (1992). WEHI3 cells were purchased from the American Type Cul-
ture Collection and BaF3/FR1 cells (Ornitz et al., 1992) were a gift from
Dr. Dave Ornitz (Washington University Medical School, St. Louis, MO).
Human recombinant FGF-2 was purified from a yeast strain expressing
this growth factor (Rapraeger et al., 1994). Heparin, NaCl, and NaClO
 
3
 
were purchased from Sigma-Aldrich. A monoclonal anti–FGF-2 antibody
specific for FGF-2 (Savage et al., 1993) and anticysteine-rich FGFR con-
trol antibody (Zuber et al., 1997) were used as described previously (Han-
non et al., 1996).
 
DNA Transfection
 
DNA was transiently transfected into MM14 cells by a calcium phosphate
DNA precipitation method as described previously (Kudla et al., 1995).
Equivalent DNA concentrations were maintained by the addition of a
pBSSK
 
1
 
 (Stratagene) plasmid. The pDCR-H-Ras (G12V) expression
vector encoding a constitutively active mutant of human Ha-Ras,
RasG12V (White et al., 1995), was provided by Dr. Channing J. Der (Uni-
versity of North Carolina, Chapel Hill, NC).
 
Clonal Growth Assay
 
MM14 cells were grown on 6-well plates to a density of 5 
 
3
 
 10
 
4
 
 and trans-
fected with the indicated expression vectors or control plasmids. Cells
were trypsinized (0.05% trypsin, 0.53 mM EDTA) and replated at clonal
density (1,000 cells per 10-cm plate) 1 h after transfection. The cells were
maintained in the presence or absence of FGF-2 (0.3 nM unless otherwise
indicated), cultured for 36 h, then processed for 
 
b
 
-galactosidase his-
tochemistry as described elsewhere (Sanes et al., 1986). The number of
cells in 
 
b
 
-galactosidase–positive clones was quantified.
 
Muscle-specific Promoter Assay
 
A differentiation-sensitive muscle-specific reporter activity assay was used
to determine the extent of MM14 differentiation after transient transfec-
tion. The reporter contained the firefly luciferase gene driven by a muscle-
specific promoter (MSP; human anti-cardiac actin promoter) (Kudla et al.,
1995). MM14 cells were assayed for luciferase activity as described previ-
ously (Fedorov et al., 1998).
 
FGF-2 Export Assay
 
To determine their FGF-2 export capabilities, transfected cells were
plated at 10
 
5
 
 cells per well in 6-well plates and incubated for 36 h in growth
media without FGF. Cells were then washed once with PBS (pH 7.2) and
incubated for 1 h at room temperature in 1 ml of BaF3/FR1 growth me-
dium supplemented with 50 
 
m
 
g/ml of heparin. The medium was then col-
lected and filtered through a 0.2-
 
m
 
m filter. BaF3/FR1 cells (10
 
4 
 
cells per
well in 24-well plates) were incubated in the collected medium for 72 h.
The number of living cells in each well was quantified by counting the
number of cells that exclude trypan blue.
 
Results and Discussion
 
MM14 cells are absolutely dependent on exogenously sup-
plied FGFs to repress myogenesis and promote prolifera-
tion, yet they express several FGFs (Hannon et al., 1996),
suggesting that the endogenously produced FGFs are inac-
cessible to FGFR-1. In addition, we have established that
distinct FGFR-1 signaling pathways mediate the prolifera-
tive and differentiation inhibitory responses in MM14 cells
(Kudla et al., 1998; Jones et al., 2000). To test the involve-
ment of Ras in both FGF-dependent pathways, MM14
cells were transiently transfected with the oncogenic Ras,
RasG12V. Ectopic Ha-Ras expression stimulated prolifer-
ation and repressed differentiation of MM14 cells in the
absence of exogenous FGF (Fig. 1). Activated Ras ap-
pears to replace only FGF-dependent signaling events
since MM14 cells transfected with oncogenic Ras were un-
able to proliferate in growth medium with reduced (2.5%)
serum (data not shown).
We hypothesized that Ha-Ras may induce FGF export
or secretion of endogenously produced FGFs and there-
fore treated MM14 cells expressing RasG12V with agents
that block FGF signaling. Addition of suramin, a nega-
tively charged polysulfonated binaphthyl urea used as a
 
1
 
Abbreviations used in this paper: 
 
FGFR, FGF receptor; HSPG, heparan
sulfate proteoglycan.
Figure 1. Ras-G12V induces MM14 cell proliferation in the ab-
sence of FGF. MM14 cells were cotransfected with plasmids en-
coding Ras-G12V ( ), pcDNA3 ( ), or pBSSK1 ( ), and 5 mg
of CMV-LacZ as described in Materials and Methods. Cells were
replated in clonal density 1 h after transfection, incubated with or
without FGF-2 (300 pM), and then fixed and scored 36 h after
transfection for LacZ-positive cells/clone. Confidence intervals (P 5
0.05) of three independent experiments, each conducted in tripli-
cate, are shown. No less than 100 clones were counted per point. 
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general heparin-binding growth factor antagonist (Lozano
et al., 1998), to cells ectopically expressing oncogenic Ras
inhibited proliferation in a dose-dependent manner (Fig. 2
A). To test the involvement of specific FGFs, MM14 cells
transiently expressing RasG12V were incubated with a
neutralizing monoclonal anti–FGF-2 antibody specific for
FGF-2 (Savage et al., 1993). Treatment with the anti–
FGF-2 antibody completely abolished the capacity of Ha-
Ras to stimulate proliferation (Fig. 2 A), whereas addition
of a control monoclonal antibody had no effect (Fig. 2 B).
Unexpectedly, we found that the ability of Ha-Ras to stim-
ulate proliferation appears dependent on extracellularly
supplied FGF-2.
FGF signaling is dependent on heparan sulfate, which
involves the interaction of heparan sulfate with both FGF
and the FGFR tyrosine kinases (Rapraeger et al., 1991;
Yayon et al., 1991; Plotnikov et al., 1999). In addition,
heparan sulfate proteoglycans (HSPGs) participate in
FGF storage, sequestration, and release (Rifkin and Mos-
catelli, 1989). Treatment of MM14 cells with sodium chlor-
ate, a reversible inhibitor of intracellular sulfation, pre-
vents FGF binding and induces terminal differentiation
(Rapraeger et al., 1991; Olwin and Rapraeger, 1992). Incu-
bation of oncogenic Ras-transfected MM14 cells with hep-
 
aritinase (not shown) or sodium chlorate significantly de-
creases cell proliferation (Fig. 3 A). Both heparitinase (not
shown) and chlorate-induced inhibition of MM14 cell pro-
liferation was rescued by addition of heparin (50 
 
m
 
g/ml),
indicating that the effect is heparan sulfate specific (Fig. 3
A). Surprisingly, addition of 600 pM FGF-2 to chlorate-
treated Ha-Ras–transfected cells promoted proliferation,
ameliorating the inhibitory chlorate effect (Fig. 3 A). This
was unexpected since addition of FGF-2 had no effect on
chlorate-treated parental MM14 cells or MM14 cells trans-
fected with a pcDNA3 vector control (Fig. 3 B). The re-
quirement for HSPGs and the ability to overcome this re-
quirement with high concentrations of exogenously added
FGF-2 suggests a more complicated role for HSPGs in ad-
dition to their known requirement for signaling. Taken to-
gether, our data demonstrate that RasG12V induces pro-
liferation of skeletal muscle cells and that induction of
proliferation requires an autocrine FGF-2 response.
Little is known regarding the mechanisms involved in
FGF-2 export since FGF-2 has no signal peptide sequence
and is not secreted through the established Golgi-dependent
secretory pathway (Mignatti et al., 1992). Instead, an unusual
ATP-dependent pathway that includes the Na
 
1
 
/K
 
1
 
-ATPase
Figure 2. Inhibition of FGF-2 signaling by suramin or an anti–
FGF-2 antibody blocks Ras-G12V–stimulated proliferation.
MM14 cells were cotransfected with the indicated expression or
control vectors, fixed, and scored as described in the legend to
Fig. 1 (1 mg Ras-G12V or pBSSK1 per well). Suramin (A), an
anti–FGF-2 antibody, and control antibody (B) were added to
Ras-G12V–transfected cells 1 h after replating. Data and confi-
dence intervals (P 5 0.05) of three (A) or four (B) independent
experiments, each conducted in triplicate, are shown. No less
than 100 clones were counted per each point.
Figure 3. Heparan sulfate proteoglycans are required for Ras-
G12V–stimulated proliferation. MM14 cells were cotransfected
with the indicated expression or control vectors, fixed, and
scored for b-galactosidase–positive clones as described in the leg-
end to Fig. 1. NaCl (30 mM), NaClO3 (30 mM), or NaClO3 and
heparin (50 mg/ml), in the presence or absence of FGF-2, were
added to transfected cells 1 h after replating. Data and confi-
dence intervals (P 5 0.05) of four (A) and two (B) independent
experiments, each conducted in triplicate, are shown for both A
and B. No less than 100 clones were counted for each point. 
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appears to be involved (Florkiewicz et al., 1998). To deter-
mine whether oncogenic Ras is directly involved in regu-
lating FGF-2 export, we asked if MM14 cells expressing
Ha-Ras exhibited increased levels of extracellular FGF-2.
Although transfection of MM14 cells with FGF-2 results in
export of biologically active FGF-2 (Hannon et al., 1996),
this extracellular FGF-2 cannot be detected in the tissue
culture media, presumably due to its strong association
with membrane-bound and extracellular matrix–associ-
ated heparan sulfate. Therefore, we have designed two as-
says to quantify FGF-2 export. One assay utilizes heparin
treatment of MM14 cells to release bound FGF-2, which is
then assayed on BaF3 cells expressing FGFR-1 (BaF3/
FR1). BaF3 cells are pre-B cells that undergo apoptosis af-
ter interleukin 3 withdrawal and do not express either
FGFRs or HSPGs. As such, these cells are unresponsive to
FGFs, unless they ectopically express FGFRs and heparin
is added as an HSPG substitute (Ornitz et al., 1992). We
found that both Ras-G12V and control (pcDNA3)-trans-
fected MM14 cells release similar levels of factor(s) that
support BaF3/FR1 survival and promote BaF3/FR1 prolif-
eration (Fig. 4). These activities are neutralized by a mono-
clonal anti–FGF-2 antibody, demonstrating that the re-
leased material is FGF-2 (Fig. 4). A second assay involves
cotransfection of MM14 cells with a construct encoding an
FGF-2–luciferase fusion protein and either Ras-G12V or a
control vector. The exported FGF-2 is quantified using a
luciferase assay after a heparin wash. The results from this
assay are indistinguishable from the BaF3/FR1 cell assay,
suggesting that similar levels of FGF-2 are exported by
control and Ha-Ras–transfected cells (data not shown).
We conclude that oncogenic Ras does not affect the level
of FGF-2 export from MM14 cells. Although MM14 cells
produce FGF-2 and export FGF-2 that can be recovered in
 
an active form, this FGF-2 is not normally available to the
cells (Hannon et al., 1996). Thus, our data suggest that ex-
ported FGF-2 is normally retained in an inactive form on
the cell surface. We propose that Ha-Ras “activates” this
inactive extracellular pool of FGF-2 either by promoting
its release from HSPGs or by providing a mechanism for
FGF-2 to gain access to cell surface FGFR-1. Although the
mechanisms involved are not understood, the ability of the
Ha-Ras mutant to promote proliferation is dependent on
exogenous FGF-2 and subsequent FGF-2–mediated sig-
naling events.
The ability of oncogenic Ras to inhibit skeletal muscle
differentiation has been well documented, but the Ras ef-
fector mediating repression of differentiation is not known
(Ramocki et al., 1998). We wanted to determine if the abil-
ity of Ras to effectively inhibit MM14 differentiation was
dependent on extracellular FGF-2, as is the proliferation
response. Addition of suramin, NaClO
 
3
 
, or the neutralizing
anti–FGF-2 antibody did not affect the ability of Ras-
G12V to repress myogenesis (Fig. 5). These data are con-
sistent with our results published previously, which demon-
strate that independent FGF signaling events mediate
repression of differentiation and proliferation (Kudla et al.,
1998; Jones et al., 2000). Thus, similar to FGFR, Ha-Ras
appears to utilize independent signaling mechanisms to re-
press terminal differentiation and promote proliferation.
Although the downstream signaling events that mediate
the repression of myogenesis by Ras are not understood, it
is well documented that oncogenic Ras stimulates secretion
of growth factors and angiogenic factors (Rak et al., 1995).
Moreover, ectopic expression of activated Ras releases a
factor that represses myogenic differentiation (Weyman
and Wolfman, 1997). Data presented in this report argue
that oncogenic Ras may be involved in the activation or re-
lease of extracellularly localized FGF-2 that is normally se-
questered in a biologically inactive state. It is noteworthy
that all of the extracellular activity observed is neutralized
Figure 4. Transfection with Ras-G12V does not stimulate export
of FGF-2 by MM14 cells. MM14 cells (105 cells per well in a 6-well
plate) were cotransfected as described in the legend to Fig. 1 (1
mg Ras-G12V, pcDNA3, or pBSSK1 per well). Cells were
washed once with BaF3/FR1 growth medium and incubated in
the same medium containing 50 mg/ml heparin for 1 h at room
temperature and then collected. BaF3/FR1 cells (104 cells per well
in a 24-well plate) were grown in conditioned medium from Ras-
G12V (CM-RasG12V;  ), pcDNA3-transfected (CM-pcDNA3;
) MM14 cells, or in control conditions (no MM14-conditioned
media; RPMI supported with 15% calf bovine serum; u) for 72 h.
Viable cells were scored based on their ability to exclude trypan
blue dye. Data and the standard deviation shown represent two
independent experiments, each performed in triplicate.
Figure 5. Blocking FGF-2 signaling by suramin, anti–FGF-2
antibody, or sodium chlorate has no effect on inhibition of differ-
entiation by Ras-G12V. MM14 cells were cotransfected with
plasmids encoding CMV-LacZ, a luciferase reporter driven by a-
cardiac actin promoter (1 mg each), and either RasG12V ( ) or
pBSSK1 ( ) (1 mg each) plasmids. Cells were incubated in the
presence or absence of FGF-2 and treated with suramin, anti–
FGF-2 antibody, or sodium chlorate as indicated (all reagents
were added 1 h after transfection). Cells were fixed and assayed
36 h after transfection. Data show fold induction of luciferase ac-
tivity relative to cells incubated in the presence of FGF-2 (equal
to 1). Each point represents three independent experiments, each
conducted in triplicate, with the standard deviations indicated. 
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by a specific blocking FGF-2 monoclonal antibody, since
proliferating MM14 cells synthesize FGF-1, -2, -6, and -7
(Hannon et al., 1996). Although detectable, FGF-2 mRNA
is present at extremely low concentrations in many adult
tissues despite the presence of high levels of FGF-2 activity,
suggesting a mechanism for retaining or storing FGF-2 in a
biologically inert form (Baird et al., 1986). Oncogenic Ras
appears to be involved in activating or releasing inactive,
extracellularly localized FGF-2. The FGF-2 produced by
skeletal muscle cells cannot be detected in the tissue cul-
ture medium, forming the basis for previous conclusions
that the Ras-secreted myogenic inhibitory factor was not an
FGF (Weyman and Wolfman, 1997). The Ras-dependent
proliferation factor we identified is released by a heparin
wash and its activity is abrogated by treatment with either
chlorate, heparitinase, suramin, or a monoclonal anti–FGF-2
antibody, implying that the proliferation factor is FGF-2.
Together with the prevalence of oncogenic Ras mutants in
rhabdomyosarcomas and the involvement of FGFs in regu-
lation of myogenesis, our data suggest that FGF-2 may be
a critical factor for supporting Ras-dependent growth of
rhabdomyosarcomas.
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